Before beginning the discussion of where this company is going, let's set expectations appropriately. Moderna won't be revisiting its all-time highs for revenue or earnings in the next three years.

It also said the alliance will see Moderna invest in R&D in the UK over the next 10 years, including running ... "It is vital we invest in fighting future variants of this disease, as well as ...

Chief Executive Officer of Moderna. "We remain focused on our three strategic priorities: driving sales growth, delivering up to 10 product approvals over the next three years, and reducing costs ...

Moderna has said it will open a new R&D and ... The facility is the centrepiece of a 10-year agreement-in-principle between the biotech and the UK government – which has been rumoured to be ...

Through a “more selective and paced approach,” Moderna looks to potentially gain 10 product approvals over the next three years while shelving advancement of other programs “until we have ...

We recently compiled a list of the 10 Firms Drop on Bearish Statements, Disappointing Earnings. In this article, we are going to take a look at where Moderna, Inc. (NASDAQ:MRNA) stands against the ...

Moderna’s vaccine “could be able to cover upwards of 70 or 80% of the norovirus outbreaks that might occur in a given year. And with our mRNA technology, we would be able to update the vaccine ...

Management's plans for the next three years entail a total of 10 product launches and, in 2027, reducing the annual sum it invests in research and development by $1.1 billion. Today, Moderna's ...